Related Experiment Video
Updated: May 25, 2026
07:41
A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
Published on: March 8, 2022
New therapeutic targets in melanoma
R M Martí1, A Sorolla, A Yeramian
1Servicio de Dermatología, Hospital Universitari Arnau de Vilanova, Universitat de Lleida, IRBLLEIDA, Lleida, Spain. marti@medicina.udl.cat
Actas Dermo-Sifiliograficas
|January 21, 2012
Summary
Targeted therapies, including BRAF inhibitors and anti-CTLA-4 antibodies, show promise for metastatic melanoma. However, challenges like drug resistance and a lack of predictive biomarkers need further research for improved patient outcomes.
Area of Science:
- Oncology
- Molecular Biology
- Immunology
Background:
- Melanoma treatment is evolving with molecularly targeted therapies.
- Significant progress has been made in identifying and utilizing specific molecular targets for drug development in metastatic melanoma.
Purpose of the Study:
- To review the efficacy of current targeted therapies in metastatic melanoma.
- To discuss the challenges and future directions in the targeted treatment of melanoma.
Main Methods:
- Review of clinical trial data for BRAF inhibitors, c-kit inhibitors, and anti-cytotoxic T lymphocyte antigen 4 (CTLA-4) antibodies.
- Analysis of resistance mechanisms and biomarker development in melanoma targeted therapy.
Main Results:
- V600E BRAF inhibitors are effective in melanomas with the V600E mutation.
- C-kit inhibitors show activity in melanomas with c-kit mutations.
- Anti-CTLA-4 antibodies demonstrate therapeutic potential by modulating immune tolerance.
Conclusions:
- Targeted therapies offer new hope for metastatic melanoma patients.
- Overcoming drug resistance and developing predictive biomarkers are critical for advancing melanoma treatment.
- Future research should focus on combination therapies and personalized treatment strategies.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
02:38Mitogens and the Cell Cycle
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
01:27Transducer Mechanism: Enzyme-Linked Receptors
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
02:34Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...